Skip to main content

Table 1 Clinical characteristics of 47 patients in the study group. A. Patient samples were labelled with a code consisting of a letter and 1, 2, 5, 6, 7 for non-preeclamptic, 3, 4 for preeclamptic patients or a Ho-number. B. Patients Ho-71, Ho- 72 and Ho-73 provided placental samples for immunogold electron microscopy

From: Proteomic studies of VEGFR2 in human placentas reveal protein associations with preeclampsia, diabetes, gravidity, and labor

Patient

Age Range

Gravida

Gestational Age (weeks)

BMI in L&D

Race

cHTN

Preeclampsia

DM

Delivery Mode

Pitocin pre-delivery

Sex F = 1

Neonatal weight (g)

A

 H1

21–25

1

38.0

30.0

6

0

0

0

1

1

1

2,940

 H2

21–25

2

37.0

24.0

8

0

0

0

1

NA

2

2,590

 H3

31–35

2

37.0

32.0

8

0

1

0

1

NA

1

3,040

 I-1

21–25

3

38.0

34.0

2

0

0

0

3

1

2

2,631

 I-2

21–25

1

42.0

30.0

1

0

0

0

1

1

2

3,759

 I-3

26–30

8

35.0

34.0

2

0

1

2

2

0

2

3,195

 I-4

18–20

1

36.6

41.0

8

0

1

0

3

0

1

3,335

 J-1

26–30

2

39.0

25.0

8

0

0

0

3

0

2

3,300

 J-2

36–40

2

37.4

22.0

1

0

0

0

1

1

1

3,460

 J-3

26–30

3

38.5

28.0

1

0

1

3

3

1

2

3,630

 L1

21–25

1

39.0

24.0

3

0

0

0

3

0

1

3,147

 L2

18–20

1

39.0

29.0

6

0

0

0

1

1

1

2,920

 L3

21–25

3

35.0

30.0

2

0

1

0

2

0

2

2,235

 L4

26–30

3

40.0

29.0

8

0

1

0

1

NA

1

3,010

 M1

21–25

3

40.1

55.0

2

0

0

0

2

0

1

3,795

 M3

18–20

2

37.0

31.3

8

0

1

0

2

0

1

3,490

 M4

26–30

1

40.1

39.8

8

0

1

0

1

1

2

3,380

 N1

31–35

4

39.1

30.0

8

0

0

2

2

0

2

3,800

 N2

31–35

2

39.3

32.8

8

0

0

0

2

0

1

3,180

 N3

31–35

2

39.0

35.5

8

0

1

0

2

0

2

3,390

 N4

18–20

2

36.4

29.5

1

0

1

0

3

1

2

3,510

 O1

21–25

2

39.3

26.2

1

0

0

0

4

1

1

2,960

 O2

21–25

1

38.4

34.8

1

0

0

0

1

1

1

2,940

 O3

26–30

1

37.1

29.5

1

0

1

0

1

1

1

2,800

 O4

21–25

3

40.3

52.5

1

0

1

0

3

1

2

3,575

 O5

36–40

4

39.1

50.4

8

0

0

3

2

0

2

4,295

 O7

32–35

12

39.3

35.2

2

0

0

0

2

0

1

3,780

 Q1

21–25

2

37.0

47.8

1

0

0

3

2

0

1

3,885

 Q2

31–35

4

39.1

35.8

2

0

0

3

2

0

1

3,390

 Q3

26–30

2

37.2

66.7

1

1

1

0

3

1

2

3,375

 Q4

31–35

4

39.1

77.2

2

0

1

3

2

0

2

3,835

 R3

21–25

1

37.6

49.5

1

1

1

0

1

1

2

2,560

 R4

26–30

4

39.1

29.8

2

0

1

2

3

1

1

3,960

 R5

21–25

6

39.0

30.9

2

0

0

0

2

0

1

3,205

 S1

26–30

2

37.4

46.2

8

0

0

2

2

0

2

4,675

 S2

26–30

3

37.5

42.2

1

0

0

2

2

0

1

4,600

 T1

26–30

5

38.0

41.9

1

0

0

2

2

0

1

3,090

 T2

26–30

1

39.1

53.3

1

0

0

2

2

0

2

3,960

 U1

31–35

3

37.1

62.6

2

1

0

2

2

0

2

4,440

 U2

26–30

3

37.1

52.7

1

1

0

2

2

0

2

5,020

 V1

36–40

5

37.1

35.5

2

1

0

0

2

0

2

2,720

 V2

36–40

2

38.4

26.1

1

0

0

0

2

0

2

4,150

 W1

18–20

1

39.2

30.5

1

0

0

0

2

0

2

3,470

 W2

26–30

8

37.0

51.7

2

1

0

0

2

0

1

3,000

B

 Ho-71

31–35

6

37.1

N/A

2

0

0

0

2

0

1

3,195

 Ho-72

26–30

1

39.3

29.4

2

 

0

3

2

NA

1

3,400

 Ho-73

26–30

1

37.0

29.1

8

0

1

0

1

1

2

2,780

  1. Abbreviations: Race: White 1, Black 2, Asian 3, Hispanic 8, unknown 6. Chronic hypertension: cHTN 1. Preeclampsia 1. Diabetes (DM): Type-1 1, Type-2 2, Gestational 3. Delivery mode: Spontaneous vaginal delivery (SVD) 1, Cesarean delivery (CD) prior to the onset of labor 2, CD after the onset of labor 3, Vaginal birth after CD (VBAC) 4. Pitocin pre-delivery 1. Fetal sex: Female 1, Male 2. L&D: Labor and delivery suite. NA, not available. The number of patients in each category were as follows: Diabetes: 30 no, Type-2 9, Gestational 5. Preeclampsia: 28 no, 16 yes. Delivery Mode: SVD 12, CD prior to the onset of labor 23, CD after the onset of labor 9, VBAC 1
Back to article page

Cell Communication and Signaling

ISSN: 1478-811X